NCT07019246 Safety of Etomidate-propofol Mixture vs. Propofol for Total Intravenous Anesthesia in Elderly Patients Undergoing Abdominal Surgery
| NCT ID | NCT07019246 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tongji Hospital |
| Condition | Etomidate Combined With Propofol |
| Study Type | INTERVENTIONAL |
| Enrollment | 166 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 166 participants in total. It began in 2025-02-01 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to access the safety of etomidate - propofol mixture vs propofol for total intravenous anesthesia in elderly patients undergoing abdominal surgery.
Eligibility Criteria
Inclusion Criteria: * ASA Ⅰ\~Ⅲ; * BMI was 18-28 kg/m2; * For elective abdominal surgery under intravenous general anesthesia; * The expected duration of anesthesia was 1 to 4 hours. Exclusion Criteria: * Septic shock and multiple organ failure diagnosed within 14 days; * Hyperkalemia (serum potassium \>5.5mmol/L) within 48 hours; * Stroke or transient ischemic attack within 3 months; * Patients with unstable angina pectoris or myocardial infarction within 3 months; Arrhythmia requiring treatment was not treated or treatment did not meet expectations; * Patients with preoperative diagnosed diabetes mellitus and uncontrolled blood glucose; Diabetic complications were diagnosed before surgery, including diabetic ketoacidosis, hyperosmolar coma, diabetes-related infection, diabetic nephropathy, retinopathy, diabetic cardiomyopathy, diabetic neuropathy, diabetic foot, etc. * Severe liver and renal dysfunction; * Liver surgery, renal surgery, adrenal surgery, day surgery; * Resting blood pressure ≥180/110 mmHg (2020 ISH hypertension guideline ≥ grade 3 hypertension); Or systolic blood pressure \<90mmHg or mean blood pressure \<65mmHg. * Taking corticosteroids or other immunosuppressants for more than 10 days within 6 months or having a history of adrenal cortex suppression or immune system diseases;
Contact & Investigator
Shiyong Li
PRINCIPAL INVESTIGATOR
Department of Anesthesiology of Tongji Hospital
Frequently Asked Questions
Who can join the NCT07019246 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 80 Years, studying Etomidate Combined With Propofol. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07019246 currently recruiting?
Yes, NCT07019246 is actively recruiting participants. Contact the research team at shiyongli@hust.edu.cn for enrollment information.
Where is the NCT07019246 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07019246 clinical trial?
NCT07019246 is sponsored by Tongji Hospital. The principal investigator is Shiyong Li at Department of Anesthesiology of Tongji Hospital. The trial plans to enroll 166 participants.